Greenwich LifeSciences Presents Breast Cancer Data
Two GLSI-100 research abstracts were accepted for the San Antonio Breast Cancer Symposium, scheduled for December 8 to 11.
Updated on Nov. 17, 2026 in Cancer

Live Poll
Do you trust scientists to deliver breakthrough cancer treatments soon?
Greenwich LifeSciences announced that two research abstracts related to its GLSI-100 breast cancer candidate were accepted for presentation at the San Antonio Breast Cancer Symposium. The company's shares rose more than 24% on the announcement.
Why it matters
GLSI-100 is being evaluated in a Phase 3 trial aimed at preventing breast cancer from returning after treatment, a population with limited options to reduce recurrence risk. Investor interest rose sharply on the news, though the presentations will be the first public look at the underlying research in this setting.
The preliminary data are company-reported and drawn from an open-label group, showing a 70% to 80% reduction in recurrence rates versus the comparator. Greenwich held $5.9 million in cash as of September 30, 2026, and the Phase 3 outcome remains unknown.
The players
Greenwich LifeSciences
A biopharmaceutical company developing GLSI-100, a HER2-derived peptide therapy aimed at preventing breast cancer recurrence after treatment.
SELLAS
A clinical-stage biopharmaceutical company whose Phase 3 REGAL trial of its GPS vaccine met its primary goal, drawing comparisons to the Greenwich approach in the same cancer space.
The details
GLSI-100 uses a peptide called GP2 derived from the HER2 protein and received U.S. Food and Drug Administration Fast Track designation in September 2025. The two accepted abstracts will be presented at the symposium, which runs from December 8 to 11 in San Antonio.
Timeline
September 2025: GLSI-100 received FDA Fast Track designation.
July: Greenwich reported preliminary recurrence-reduction data.
September 30, 2026: Greenwich reported a $5.9 million cash balance.
Monday: Greenwich reported a third-quarter loss of $0.40 per share.
Tuesday: Greenwich shares surged more than 24% after the symposium announcement.
Health Landscape
The SELLAS Phase 3 REGAL trial of its GPS vaccine reduced the risk of death by 41%, with median overall survival of 24 months against 14.7 months for best available treatment. Greenwich's GLSI-100 is an alternative peptide approach being tested to prevent recurrence, placing it among the newer recurrence-prevention candidates in breast and related cancers.
For patients who have completed breast cancer treatment, a therapy that lowers recurrence would address one of the most pressing ongoing concerns. Any eventual availability will depend on Phase 3 results, regulatory review, and insurance coverage, none of which are settled yet.
The takeaway
Investors reacted strongly to the symposium news, but the Phase 3 Flamingo-01 trial will determine whether preliminary recurrence reductions hold. Readers should weigh early open-label data as promising but not yet confirmed.
Further reading
For broader context on recurrence-prevention research, explore Cancer coverage across the site.
Source note: This article includes information reported by Asianet News Network Pvt Ltd.
Live Poll
Do you trust scientists to deliver breakthrough cancer treatments soon?










